<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829959</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0624</org_study_id>
    <nct_id>NCT00829959</nct_id>
  </id_info>
  <brief_title>Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)</brief_title>
  <official_title>Attitudes About Childbearing And Fertility In Women Seeking Genetic Testing For Inherited Breast And Ovarian Cancer Syndromes (HBOC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      - To evaluate the attitudes and opinions of women undergoing genetic counseling for&#xD;
      hereditary breast and ovarian cancer syndrome, both before and after testing, in regards to&#xD;
      pregnancy and fertility&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      -Factors that will increase the percentage of women endorsing prenatal diagnostic testing&#xD;
      will include a personal history of breast or ovarian cancer, having had a mother or sister&#xD;
      die of breast or ovarian cancer, and testing positive for a BRCA mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This questionnaire is part of a study at The University of Texas M.D. Anderson Cancer Center.&#xD;
      The purpose is to ask women who are seeking genetic testing for HBOC their viewpoints&#xD;
      surrounding fertility, childbearing and parenting, both at the time of testing and at the&#xD;
      time of results disclosure. The aim is to evaluate if the genetics results disclosure may&#xD;
      influence women's views regarding these topics. Researchers hope to use this information to&#xD;
      provide more information to the patient and the caregiver to help both parties with this very&#xD;
      important cancer survivorship issue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Women Endorsing Prenatal Diagnostic Testing (Questionnaire response)</measure>
    <time_frame>Baseline and post genetic testing (results disclosure) at 3-4 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">156</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Genetic Counseling</arm_group_label>
    <description>Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>1 - 2 questionnaires, lasting 10-15 minutes.</description>
    <arm_group_label>Genetic Counseling</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing genetic counseling within UT MDACC Clinical Cancer Genetics Program for&#xD;
        hereditary breast and ovarian cancer syndrome (HBOC).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women who have been referred to the Clinical Cancer Genetics Program for discussion of&#xD;
             Hereditary Breast And Ovarian Syndrome (HBOC).&#xD;
&#xD;
          2. Participants must be seen by clinical cancer geneticist and undergo genetic counseling&#xD;
             here at M.D. Anderson Cancer Center for HBOC.&#xD;
&#xD;
          3. Participants may or may not have a personal diagnosis of cancer.&#xD;
&#xD;
          4. Participants may have already seen or undergone reproductive endocrine evaluation and&#xD;
             had any reproductive treatment.&#xD;
&#xD;
          5. The participant must be a woman and have reproductive potential which would include&#xD;
             either active menstruation, blood tests with premenopausal ranges of Luteinizing&#xD;
             Hormone (LH), Follicle Stimulating Hormone (FSH) and estradiol, or was premenopausal&#xD;
             prior to starting chemotherapy for a diagnosed breast cancer.&#xD;
&#xD;
          6. Age &gt;/= 18 years old&#xD;
&#xD;
          7. The patient must be able to speak and read fluently in either English or in Spanish in&#xD;
             order to complete the questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Litton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovary, Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Hereditary Breast and Ovarian Cancer Syndrome</keyword>
  <keyword>HBOC</keyword>
  <keyword>Genetic testing</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Fertility</keyword>
  <keyword>Prenatal diagnostic testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

